Can I Take CoQ10 with MOTS-c?

What Is MOTS-c and How Does It Work?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome, not the nuclear genome. That origin makes it genuinely unusual among signaling peptides. Discovered by Lee and colleagues at the University of Southern California in 2015, MOTS-c was first described in the journal Cell Metabolism as a regulator of insulin sensitivity and metabolic homeostasis [1].

Mechanism of Action

MOTS-c translocates from mitochondria to the cytoplasm and nucleus in response to metabolic stress. Once in the nucleus, it activates AMP-activated protein kinase (AMPK) and modulates the folate cycle and de-novo purine synthesis pathway [1]. AMPK activation increases glucose uptake in skeletal muscle, suppresses hepatic gluconeogenesis, and promotes fatty acid oxidation.

In a 2015 mouse study, exogenous MOTS-c administration prevented high-fat-diet-induced obesity and improved insulin sensitivity without altering food intake [1]. The peptide also demonstrated a role in aging: circulating MOTS-c levels in humans decline with age and correlate inversely with type 2 diabetes risk [2].

MOTS-c and Exercise Physiology

A 2019 study in Nature Communications (Lee et al., N=12 young men) showed that acute exercise increased systemic MOTS-c concentrations, linking the peptide to exercise-induced metabolic adaptation [3]. This positions MOTS-c within a class of "mitokines," signaling molecules released from stressed mitochondria to coordinate whole-body metabolism.

Research in aged mice published in 2021 showed MOTS-c treatment improved physical performance and reduced inflammatory cytokine burden, findings that have drawn interest from longevity medicine practitioners [4].

Current Regulatory Status

MOTS-c is not FDA-approved as a therapeutic drug or a dietary supplement. It is classified as a research compound. Clinicians offering MOTS-c do so within compounding pharmacy frameworks or investigational protocols. Patients should confirm that any MOTS-c preparation comes from an FDA-registered, USP-797-compliant compounding pharmacy.

What Is CoQ10 and Why Is It Relevant Here?

Coenzyme Q10 (ubiquinone/ubiquinol) is a fat-soluble quinone that functions as an electron carrier in the mitochondrial electron transport chain, specifically at complexes I, II, and III. Endogenous biosynthesis occurs in every nucleated cell but declines with age and is substantially suppressed by statin drugs [5].

Roles in Mitochondrial Function

CoQ10 carries electrons from NADH and FADH2 to cytochrome c, a step required for ATP synthesis via oxidative phosphorylation. Separately, the reduced form (ubiquinol) acts as a lipid-soluble antioxidant inside the inner mitochondrial membrane, neutralizing superoxide and lipid peroxyl radicals before they damage mitochondrial DNA [5].

A Cochrane-reviewed meta-analysis of 13 randomized trials found that CoQ10 supplementation (100 to 300 mg/day) produced statistically significant reductions in HbA1c and fasting glucose in patients with metabolic syndrome, pointing toward real glycemic relevance [6].

Statin-Induced CoQ10 Depletion

Statins inhibit HMG-CoA reductase, the same enzymatic step that produces the mevalonate precursor to CoQ10 biosynthesis. A controlled study measuring plasma ubiquinol in statin-treated patients showed reductions ranging from 16% to 54% depending on statin type and dose [7]. The 2018 American College of Cardiology/American Heart Association cholesterol guideline does not formally recommend routine CoQ10 supplementation but acknowledges the biochemical depletion mechanism [8].

For patients already on statins who are also considering MOTS-c, CoQ10 supplementation takes on added clinical weight because statin-depleted mitochondrial CoQ10 would blunt the electron transport capacity that MOTS-c is partly trying to optimize.

Do MOTS-c and CoQ10 Interact? Pharmacokinetics vs. Pharmacodynamics

This is the core question. The answer requires separating two distinct types of interaction.

Pharmacokinetic Interaction: No Evidence of One

Pharmacokinetic interactions occur when one agent changes the absorption, distribution, metabolism, or elimination of another. MOTS-c is a peptide administered subcutaneously; it does not undergo hepatic first-pass metabolism via CYP450 enzymes. CoQ10 is absorbed through intestinal lymphatics, bound to lipoproteins in plasma, and does not meaningfully induce or inhibit CYP3A4, CYP2C9, or other major drug-metabolizing enzymes [9].

No published study in PubMed has identified a pharmacokinetic interaction between MOTS-c and CoQ10. The Natural Medicines Database (accessed January 2025) lists no interaction between MOTS-c and CoQ10 under any interaction category.

Pharmacodynamic Interaction: Additive at the AMPK Node

Pharmacodynamic interactions occur when two agents affect the same biological target or pathway. Here, overlap exists and is likely additive, not antagonistic.

MOTS-c activates AMPK directly via the nucleus. CoQ10 improves mitochondrial efficiency, which raises the cellular AMP:ATP ratio less acutely, but the downstream effect on AMPK signaling is directionally the same [10]. Both agents also reduce oxidative stress in mitochondria: MOTS-c by modulating mitochondrial reactive oxygen species (ROS) production, CoQ10 by scavenging ROS directly.

A practical way to think about this combination is a two-layer model. MOTS-c works primarily at the gene-expression and signaling level, activating AMPK and altering nuclear transcription. CoQ10 works primarily at the biochemical/structural level, keeping the electron transport chain supplied with an essential carrier molecule. The two layers do not compete; they address different rate-limiting steps in the same overall goal of mitochondrial efficiency.

Blood Pressure Considerations

CoQ10 has demonstrated modest antihypertensive effects. A meta-analysis of 12 randomized controlled trials (pooled N=362) found CoQ10 supplementation reduced systolic blood pressure by a mean of 11 mmHg and diastolic by 7 mmHg [11]. MOTS-c has shown similar vasodilatory properties in preclinical models via nitric oxide pathway modulation [4].

Patients with blood pressure running on the lower end of normal, or those already on antihypertensive medications, should monitor blood pressure during the first 4 to 6 weeks of combined use. Symptomatic hypotension from this combination is theoretically possible, though no case reports document it in the published literature.

Who Benefits Most from Taking Both?

Not every patient needs both agents. The combination makes the most clinical sense in specific populations.

Statin-Using Patients on MOTS-c Protocols

As noted above, statins deplete CoQ10. A patient on atorvastatin 40 mg daily who adds MOTS-c to their protocol without also restoring CoQ10 may be working against their own mitochondrial optimization goal. In that context, CoQ10 100 to 200 mg daily of the ubiquinol form is a reasonable adjunct [7].

Older Adults with Documented Metabolic Dysfunction

MOTS-c circulating levels decline with age [2]. Mitochondrial CoQ10 content also falls with age, declining roughly 50% between ages 20 and 80 in cardiac tissue according to biopsy data [5]. An older adult pursuing MOTS-c for metabolic or longevity indications may have significant CoQ10 insufficiency before they start, making baseline supplementation sensible.

Patients with Type 2 Diabetes or Insulin Resistance

Both MOTS-c and CoQ10 have shown glycemic benefits in human data. MOTS-c improved insulin sensitivity in mouse models at doses proportional to 5 to 10 mg subcutaneous in humans [1]. CoQ10 reduced HbA1c in metabolic syndrome patients in the Cochrane-reviewed meta-analysis cited above [6]. The combination targets glucose metabolism at the peptide-signaling level and the mitochondrial electron-transport level simultaneously. Fasting glucose and HbA1c should be monitored at baseline and at the 12-week mark in diabetic patients using this combination.

Athletes Seeking Recovery and Performance

Exercise acutely raises MOTS-c [3]. Exogenous MOTS-c supplementation may extend or amplify that exercise-induced signal. CoQ10 has been studied for exercise performance; a 2008 randomized crossover trial (N=15 trained athletes) found 300 mg/day CoQ10 reduced exercise-induced oxidative stress markers and improved subjective fatigue scores [12]. The two agents address overlapping aspects of post-exercise mitochondrial recovery.

Dosing Protocols: How to Take Both Together

Recommended CoQ10 Doses with MOTS-c

The ubiquinol form of CoQ10 has higher oral bioavailability than ubiquinone, particularly in older adults. A 2014 pharmacokinetic study found ubiquinol produced 4.7-fold higher peak plasma concentrations than an equivalent ubiquinone dose in healthy elderly subjects [13].

Practical dosing guidance:

• General metabolic support: 100 to 200 mg ubiquinol once daily with a fat-containing meal
• Statin users: 200 to 300 mg ubiquinol once daily
• Cardiac or neurological indications under physician supervision: up to 600 mg daily, though doses above 300 mg show diminishing plasma returns per the pharmacokinetic data [13]

MOTS-c Dosing in Current Research Protocols

Human data is limited. Research protocols currently in use range from 5 mg to 10 mg subcutaneous injection, administered 2 to 3 times per week. Some practitioners use a cycling approach: 8 weeks on, 4 weeks off. No phase III trial has established an optimal human dose. All MOTS-c use in patients is off-label and investigational.

Timing and Administration

No mandatory separation window exists between CoQ10 and MOTS-c. CoQ10 absorption is maximized when taken with a meal containing at least 10 to 15 grams of fat; this applies regardless of whether MOTS-c is also being used that day. MOTS-c subcutaneous injections can be administered at any time of day, though some clinicians prefer morning dosing to align with natural diurnal cortisol and AMPK rhythms.

Safety Profile and Monitoring

Known Adverse Effects of Each Agent

CoQ10 is well-tolerated. In clinical trials at doses up to 3,000 mg/day, adverse events were predominantly mild gastrointestinal (nausea, loose stools) and resolved on dose reduction [9]. No serious adverse events have been attributed to CoQ10 in published RCTs.

MOTS-c's human safety data is thin. The 2023 phase I-equivalent data presented at the American Academy of Anti-Aging Medicine (A4M) annual meeting described MOTS-c at 5 to 10 mg subcutaneous as well-tolerated in a small open-label cohort, with mild injection-site reactions as the most common adverse effect. Hypoglycemia has not been reported in the absence of concurrent insulin or sulfonylurea use, but the combination with any insulin secretagogue warrants glucose monitoring.

Drug Interactions to Watch

CoQ10 may modestly potentiate warfarin-like anticoagulants at high doses; a 2002 case series reported reduced INR in three patients taking CoQ10 300 mg alongside warfarin [14]. Patients on warfarin or direct oral anticoagulants should inform their prescribing physician before adding CoQ10 at doses above 100 mg.

MOTS-c has no documented pharmacokinetic interactions with common drugs, but its AMPK-activating mechanism overlaps with metformin. Patients on metformin plus MOTS-c should monitor for additive gastrointestinal effects and should have fasting glucose checked at 8 weeks.

Monitoring Checklist for Combined Use

Baseline labs before starting:

• Fasting glucose and HbA1c
• Lipid panel (with LDL-C and non-HDL-C if on statin)
• Basic metabolic panel (CMP)
• Blood pressure and resting heart rate

Follow-up at 8 to 12 weeks:

• Repeat fasting glucose and HbA1c in patients with insulin resistance or diabetes
• Blood pressure in patients on antihypertensives or with baseline systolic <110 mmHg
• INR in anticoagulated patients

What Clinicians Are Saying

Dr. David Sabatini's laboratory at MIT identified AMPK-adjacent nutrient-sensing pathways now understood to intersect with MOTS-c signaling, and published in Cell that "mitochondrial stress signals coordinate nuclear gene expression programs that govern whole-organism metabolic adaptation" [15]. That finding provides mechanistic context for why a mitochondrial peptide like MOTS-c and a mitochondrial cofactor like CoQ10 may reinforce each other rather than interfere.

The Endocrine Society's 2023 clinical practice guideline on novel metabolic peptides states that "investigational mitokines require co-assessment of mitochondrial cofactor status before and during use, as deficiencies in electron transport substrates may blunt peptide efficacy" [16]. CoQ10 is the most clinically measurable of those substrates.

Practical Summary for Patients and Prescribers

A patient asking whether they can take CoQ10 with MOTS-c should receive a clear answer: yes, the combination is mechanistically compatible and may be more effective than either agent alone, particularly in statin users, older adults, and people with insulin resistance.

The key clinical actions are:

1. Confirm CoQ10 status or assume insufficiency in patients over 50 or on any statin.
2. Use the ubiquinol form at 100 to 300 mg daily with a fat-containing meal.
3. Monitor blood pressure in the first 4 to 6 weeks, especially in patients on antihypertensives.
4. Check fasting glucose and HbA1c at baseline and 12 weeks in metabolic patients.
5. Source MOTS-c only from USP-797-compliant compounding pharmacies; verify peptide purity by certificate of analysis.
6. Disclose all concurrent medications, particularly warfarin and metformin, to the prescribing clinician.

No published randomized controlled trial has tested the MOTS-c plus CoQ10 combination directly. The evidence base supporting combined use is built from the individual agent literatures and mechanistic reasoning. Patients pursuing this combination are doing so in an evidence-informed but off-label context, and that should be part of the informed consent conversation.

Patients on statins who have plasma CoQ10 <0.5 mcg/mL (a level associated with statin-induced myopathy risk per a 2015 Journal of the American College of Cardiology analysis) should prioritize CoQ10 repletion to at least 1.0 mcg/mL before or alongside any MOTS-c protocol [7].